Bioelectronic Medicine on the Rise

Bioelectronic medicine could be one of healthcare’s biggest secrets. The space is filled with applications – but many aren’t mainstream yet. A panel titled “ Bioelectronic Medicine: Redefining Medical Treatment,” will be held Tuesday, February 11, from 2:05 to 3:00 p.m. in Room 210A at MD&M West Anaheim to discuss the space and how it could impact healthcare. While there have been some significant movements in that time – perhaps one of the greatest has developments has been GlaxoSmithKline teaming up with Verily Lifesciences to form the Galvani Bioelectronics joint venture in 2016. This move helped to open up the floodgates for technologies coming out of the space. Recently there have been a number of companies and technologies stepping up to the plate. Neuro Sigma’s Monarch external Trigeminal Nerve Stimulation (eTNS) System made history in 2019 when it became the first device to win a nod from FDA to treat attention deficit hyperactivity disorder (ADHD). Monarch is about the size of a cellphone. The device generates a low-level electrical pulse and connects via a wire to a small patch that adheres to a patient's forehead, just above the eyebrows, and should feel like a tingling sensation on the skin. Fempulse made an impact in the bioelectronic medicine market with therapy for the personalized treatment of overactive bladder (OAB) in women. The Minn...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Electronics Source Type: news

Related Links:

Authors: Merrigan SL, Park B, Ali Z, Jensen LD, Corson TW, Kennedy BN Abstract Aberrant ocular angiogenesis can underpin vision loss in leading causes of blindness, including neovascular age-related macular degeneration and proliferative diabetic retinopathy. Current pharmacological interventions require repeated invasive administrations, may lack efficacy and are associated with poor patient compliance and tachyphylaxis. Vitamin D has de novo anti-angiogenic properties. Here, our aim was to validate the ocular anti-angiogenic activity of biologically active vitamin D, calcitriol, and selected vitamin D analogue, 2...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: January 2020Source: Pregnancy Hypertension, Volume 19Author(s): Sarah Novotny, Nicole Lee-Plenty, Kedra Wallace, Wondwosen Kassahun-Yimer, Aswathi Jayaram, James A. Bofill, James N. MartinAbstractObjectiveTo determine the prevalence of acute kidney injury (AKI), placental abruption and postpartum hemorrhage in patients with preeclampsia or HELLP syndrome.Study designA retrospective study of patients with preeclampsia or HELLP syndrome treated at the University of Mississippi Medical Center from January 2000 through December 2010.Main outcome measuresRelationships among the obstetric complications of place...
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
Publication date: January 2020Source: Pregnancy Hypertension, Volume 19Author(s): Laura A Magee, Joel Singer, Terry Lee, Richard J McManus, Sarah Lay-Flurrie, Evelyne Rey, Lucy C Chappell, Jenny Myers, Alexander G Logan, Peter von DadelszenAbstractObjectiveTo examine the relationship between pregnancy outcomes and BP level and variability.DesignSecondary analysis of CHIPS trial data (Control of Hypertension In Pregnancy Study, NCT01192412).SettingInternational.Population or sampleWomen with chronic or gestational hypertension.MethodsBP measurement was standardised in outpatient clinics. Adjusted (including for allocated gr...
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
Publication date: January 2020Source: Pregnancy Hypertension, Volume 19Author(s): Cecilia Villalain, Ignacio Herraiz, Borja Cantero, Soledad Quezada, Ana Lopez, Elisa Simón, Alberto GalindoAbstractObjectivesThe optimal timing for delivery in non-severe late-preterm (34 + 0–36 + 6 weeks) preeclampsia (PE) is uncertain. It is attempted to reach term pregnancy safely but current clinical and analytical parameters fail to determine which cases will develop severe features that require preterm delivery. We aim to establish if angiogenic biomarkers may identify cases that would benefit from ...
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
Publication date: January 2020Source: Pregnancy Hypertension, Volume 19Author(s): Mohamed Rezk
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
Publication date: January 2020Source: Pregnancy Hypertension, Volume 19Author(s): Ellie Proussaloglou, Ariel Mueller, Ruby Minhas, Sarosh RanaAbstractObjectivesHypertensive disorders of pregnancy are a leading cause of maternal morbidity and mortality. Although acute severe hypertension carries with it a poor prognosis, treatment is often delayed and not universal.Study designA total of 654 patients were assessed for the impact of hypertensive disorders of pregnancies on maternal and fetal morbidity and divided into three groups: normotensive (Group I, N = 306), non-severe hypertension (Group II, N = 24...
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
ConclusionAspirin resistance was found in a considerable part of the participants. Considerable variation between participants, within participants over time and between the different devices was found. Prevalence of aspirin resistance during pregnancy differs from after pregnancy. More research on aspirin resistance and clinical obstetric outcome is needed.
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
ConclusionsCardiac effects after severe late-onset PE were small and transient. This indicates that left ventricular hypertrophy after severe late-onset PE may be a secondary physiologic response to increased peripheral resistance in PE. Vascular mechanisms rather than persistent cardiac hypertrophy postpartum may be the culprit for increased long-term cardiovascular risk after PE.
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
In conclusion, our data suggests that progression to kidney disease might not be a major concern in women after preeclampsia within 18 years postpartum.
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
Publication date: January 2020Source: Pregnancy Hypertension, Volume 19Author(s): Zain Awamleh, Victor K.M. HanAbstractPreeclampsia (PE) and intrauterine growth restriction (IUGR) are pregnancy complications resulting from abnormal placental development. As epigenetic regulators, microRNAs can regulate placental development and contribute to the disease pathophysiology by influencing the expression of genes involved in placental development or disease. Our previous study revealed an increase in miR-210-5p expression in placentae from patients with early-onset pregnancy complications and identified candidate gene targets fo...
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
More News: Acid Reflux | ADHD | Brain | Diabetes | Diabetes Type 2 | Endocrinology | Gastroenterology | Gastroesophageal Reflux Disease | GERD | Hyperactivity | Hypertension | Italy Health | Medical Devices | Neurology | Overactive Bladder | Overactive Bladder Syndrome | Skin | Study | Women